Authors’ replyBMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2445 (Published 18 April 2011) Cite this as: BMJ 2011;342:d2445
- Anjali Amin, specialist registrar, diabetes and endocrinology1,
- Karim Meeran, professor of endocrinology1
- 1Imperial Centre for Endocrinology, London W6 8RF, UK
Competing interests: None declared.
Grant suggests that tolvaptan could reduce hospital stay in acute neurosurgical patients,1 but quotes a study on patients with heart failure.2 He indicates that one tolvaptan tablet could reduce hospital stay by more than two days. But the study found that daily administration …